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We demonstrated previously that Calu-3 airway epi-
thelial cells sense adenosine on their luminal surface
through adenosine A2B receptors coupled to adenylyl
cyclase. Occupancy of these receptors leads to activa-
tion of the cystic fibrosis transmembrane conductance
regulator (CFTR) chloride channel through protein ki-
nase A (PKA) anchored at the apical membrane. Because
luminal A2B receptor activation does not raise total cel-
lular cAMP levels, we hypothesized that activation of
phosphodiesterases (PDEs) confines cAMP generated by
apical A2B receptors to a microdomain that includes the
CFTR channel. Using reverse transcription-PCR, West-
ern blotting, and activity measurements, PDE4D was
identified as the major PDE species in airway epithelia.
Consistent with these results, inhibitors of PDE4, but
not PDE3, selectively abolished the lateral confinement
of cAMP signaling in apical membrane patches during
cell-attached recordings. Furthermore, stimulation of
the CFTR in excised apical patches by rolipram and
RS25344 indicated that PDE4 is localized in close prox-
imity to the CFTR channel. Indeed, immunohistochem-
istry of human airway sections revealed that PDE4D is
localized in the apical domain of the cell. PDE4 was
activated after luminal adenosine exposure in a PKA-de-
pendent manner. Because PDE4 activity is positively
regulated by PKA, our results support a model whereby
the PDE diffusion barrier is proportional to the degree
of receptor stimulation. These findings underscore the
concept that subcellular localization of individual PDE
isozymes is an important mechanism for confining
cAMP signaling to functional domains within cells.
Numerous cellular processes are initiated, modulated, or
terminated by cAMP (1). Acting on receptors and transducers,
diverse extracellular stimuli elicit cAMP production by mem-
brane-bound adenyl cyclases, but the spatial and temporal
organization required to tailor cAMP signaling to individual
cellular responses is not completely understood. In the case of
the cystic fibrosis transmembrane conductance regulator
(CFTR),1 we reported previously that luminal adenosine ele-
vated juxtamembrane cAMP levels and stimulated the activity
of protein kinase A (PKA) to increase CFTR open probability (2,
3). Furthermore, we showed that this signaling is dependent on
the close proximity of each of these signaling components be-
cause cAMP-dependent stimulation of the CFTR initiated by
adenosine A2B receptors requires locally anchored PKA (4).
Interestingly, our patch clamp experiments also indicated that
apical A2B receptors excluded from cell-attached patches did
not modulate the CFTR within cell-attached patches (2). This
result suggests that diffusion of cAMP near the apical cell
membrane is constrained in a manner similar to that observed
in other model systems (5, 6).
The orchestration of signal transduction via the assembly of
signaling protein complexes has been described for many cell
systems (7). Signaling proteins are frequently organized into
multi-protein complexes responsible for signal amplification or
pathway specification as in the case of G protein-coupled re-
ceptors and calcium channels (8, 9). In epithelial cells, a com-
plex composed of B2 adrenergic receptors, adenyl cyclase, PKA,
and CFTR may be formed via interaction with A kinase-an-
choring proteins (AKAPs) and the ezrin/moesin/radixin-bind-
ing protein, EBP50 (10). This complex promotes rapid cAMP-
dependent phosphorylation and activation of the channel. In
many instances, PKA also is associated with proteins involved
in inactivation of effector proteins. For example, protein phos-
phatases can also directly bind AKAPs to promote rapid and
specific dephosphorylation of specific substrates (11). Phos-
phodiesterases (PDEs), the enzymes that degrade and inacti-
vate cAMP, have been found recently in complex with AKAPs
and PKA (12, 13). This localization of PDEs in close proximity
to PKA is thought to control the access of cAMP to binding sites
on the regulatory subunit of the kinase (14, 15). PDEs are
subdivided into 11 subgroups based on pharmacologic and
structural properties, each varying in their regulation and
cyclic nucleotide specificity (16). Although data exist concern-
ing a role for phosphodiesterases in the compartmentation of
cAMP in nonpolarized cells (17–19), little is known about the
distribution and actions of cAMP in microdomains such as the
apical regions of polarized epithelia. Several PDEs are ex-
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pressed in both human airway and intestinal epithelia based
on molecular (20, 21) and pharmacologic approaches (22, 23).
At least one PDE, PDE3, can augment CFTR responses ex vivo
(24), in some animal models (25), but not in humans (26). To
define the role of PDE4 in signal compartmentalization in
polarized cells, we extended our previous observations with
regard to local cAMP signaling in human airway epithelium
and assessed the impact of PDEs in limiting apical cAMP
signaling and the regulation of CFTR. We find that PDE4D is
a critical component of cAMP signaling at the apical membrane
that controls the diffusion of cAMP from its site of generation
and that this control is modulated through PKA activation.
EXPERIMENTAL PROCEDURES
Reagents and Chemicals—All chemicals were purchased from either
Sigma or Calbiochem unless otherwise noted. RS25344 was a generous
gift of Roche Applied Science.
Cells—Human Calu-3 cells were seeded as described previously (2)
on Costar clear transwells or homemade permeable supports (12-mm
diameter for cAMP assays and 1.5-mm diameter for patch clamp stud-
ies), grown until confluent, and polarized with a resistance greater than
100 ohmcm2.
Single-channel Studies—The procedures were essentially as de-
scribed previously (2). Briefly, CFTR Cl channel activity was recorded
at a membrane potential of 60 mV. For cell-attached recording, both the
pipette and the bath contained 160 mM TrisCl and 30 mM sucrose, pH
7.0. The resistance of an open pipette was 6–8 megaohms. Tests of
adenosine (ADO) or forskolin outside the pipette were made by cumu-
lative additions to the bath as indicated. For outside-out recording, both
the pipette and the bath solutions were the same as described previ-
ously (2). Adenosine 5-[,-methylene]diphosphate (AMPCP) was pres-
ent at 0.3 mM in pipette and bath solutions in both recording
configurations.
Ussing Chamber Studies—CFTR-mediated Cl secretion was meas-
ured as described previously (27). Briefly, cells grown on collagen mem-
brane supports were mounted in conventional Ussing chamber devices.
The submucosal bathing solution was Krebs bicarbonate Ringer’s solu-
tion, and the mucosal solution was low-Cl (3 mM) Krebs bicarbonate
Ringer’s solution with gluconate. Bioelectric properties were digitally
recorded from the output of voltage clamps (no. VCC600; Physiologic
Instruments, San Diego, CA) using ACQUIRE software (Physiologic
Instruments). Voltage was clamped to 0 mV except for 3-s pulses to 10
mV every 60 s. Tissue conductance was calculated from the resulting
current deflections. For each experiment, basal properties were re-
corded for 20–40 min. Test compounds (ADO, cilostamide, RS25344,
and so forth) were added to the low-Cl luminal bath. Maximum cAMP-
dependent Isc (short circuit current) was recorded after bilateral expo-
sure to 10 M forskolin. Relative potency was determined by fitting
curves to the fractional changes induced by sequentially increasing
concentrations of test substances relative to the response to forskolin.
These conditions resulted in a basal CFTR-mediated Isc of 30–40 A/
cm2 and a maximally stimulated CFTR current of 150–200 A/cm2.
PDE Assay—Polarized Calu-3 cells were lysed in SB1 buffer (50 mM
HEPES, pH 7.4, 250 mM NaCl, 10% glycerol, 0.5% Nonidet P-40, 1 mM
EDTA, 0.2 mM EGTA, 10 m NaF, 10 mM Na4P2O7, 1 M microcystin, 2
mM 4-(2-aminoethyl) benzenesulfonylfluoride, and a mixture of prote-
ase inhibitors). The cell lysates were spun at 14,000  g, and superna-
tants were immunoprecipitated using 15 l of protein G-Sepharose
bound to 5 l of the following PDE4 antibodies: rabbit anti-4D3, rabbit
anti-4D5, pan-4A (AC55), pan-4B (K118), or pan-4D (M3S1). PDE ac-
tivity was measured as described previously (28). In brief, samples were
assayed in a reaction mixture of 200 l containing 40 mM Tris-HCl, pH
8.0, 10 mM MgCl2, 5 mM -mercaptoethanol, 1 M cAMP, 0.75 mg/ml
bovine serum albumin, and 0.1 Ci of [3H]cAMP for 10 min at 33 °C.
The reaction was terminated by the addition 200 l of 10 mM EDTA in
40 mM Tris-HCl, pH 8.0, followed by heat inactivation in a boiling water
bath for 1 min. The PDE reaction product 5-AMP was then hydrolyzed
by incubation of the assay mixture with 50 g of Crotalus atrox snake
venom for 20 min at 33 °C. The resulting adenosine was separated by
anion exchange chromatography using 1 ml of AG1-X8 resin and quan-
titated by scintillation counting.
Immunostaining—Human trachea sections were provided by the
University of North Carolina Cystic Fibrosis Center Histology Core
Facility, and immunostaining was performed as described previously
(29) with modifications. Briefly, frozen tissue sections were fixed in 4%
paraformaldehyde at room temperature (4 min), permeabilized in 100%
FIG. 1. Phosphodiesterase activity
in Calu-3 cells. Polarized Calu-3 cells
grown on transwell supports were lysed
in the SB1 buffer and assayed for PDE
activity. A, shown are total Calu-3 phos-
phodiesterase activity from cell lysates,
rolipram-sensitive activity in the lysates,
cilostamide-sensitive activity, and activ-
ity not inhibited by either compound. B,
total PDE4 activity contrasted against
the contribution of each PDE4 family
member based on immunoprecipitation
using antisera specific for each member.
Error bars, S.E. C, Western blot analysis
of PDE4D expression in Calu-3 and cul-
tured human airway cells.
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ethanol at 20 °C (4 min), and blocked in 20% goat serum in phosphate-
buffered saline for 3 h. Sections were then incubated in primary anti-
serum (pan-4D (M3S1) or rabbit anti-4D5) or pooled normal rabbit IgGs
diluted in phosphate-buffered saline for 16 h at 4 °C. This was followed
by phosphate-buffered saline washes and incubation with Alex594-
conjugated goat anti-rabbit or anti-mouse IgG (Molecular Probes,
Eugene, OR) for 1 h at room temperature. Tissues were mounted in
Vectashield (Vector Laboratories, Inc., Burlingame, CA). Paraffin-
embedded sections also were processed as described previously (30).
Photomicrographs were taken using a Leica TCS 4D confocal micro-
scope at powers indicated in the figure legends. All images were
captured and analyzed using Adobe Photoshop.
Western Blotting—PDE proteins were immunoprecipitated using
PDE4 isoform-specific or pan-PDE4 antisera. Precipitated proteins
were washed extensively and analyzed by Western blot using the pan-
PDE4D monoclonal antibody (generously provided by ICOS, 1:5000),
rabbit anti-4D3 antibody, or anti-4D5 polyclonal antibody as described
previously (31).
Reverse Transcription-PCR—RNA was extracted from cells using the
RNeasy Mini Kit (Qiagen, Inc., Valencia, CA) after RNAlater treatment
(Ambion, Austin, TX). Genomic DNA contamination was removed by
DNase treatment. Sample RNA was quantified by spectrophotometry,
and 200 ng was reverse-transcribed to cDNA in a total reaction volume
of 22 l. Briefly, a mixture of 200 ng of total RNA, 200 ng of random
primers (Invitrogen), and 10 mmol of deoxynucleotide triphosphate in a
total volume of 12 l was denatured at 65 °C for 5 min and then
incubated for 10 min at room temperature and 2 min at 42 °C with 4 l
of 5 First-Strand Buffer, 2 l of 0.1 mM dithiothreitol (Invitrogen), and
40 units of RNase inhibitor (Promega). Two hundred units of Super-
Script II reverse transcriptase (Promega) was added, and the mixture
was incubated for 50 min at 42 °C. Finally, the mixture was incubated
for 15 min at 70 °C to inactivate the enzyme. Primers and conditions
used to amplify each of the phosphodiesterase isoforms can be supplied
upon request.
cAMP Assay—Before ADO stimulation, Calu-3 cells were incubated
for 1 h in serum-free Opti-MEM (Invitrogen) containing AMPCP and
either cilostiamine, RS25344, or neither. Cells were then stimulated for
5 min with 10 M ADO at 37 °C. This was followed by cell lysis and
cAMP enzyme immunoassay (Amersham Biosciences) according to the
manufacturer’s recommendation.
RESULTS AND DISCUSSION
In preliminary patch clamp experiments, we used a pharma-
cological approach to determine which PDE gene families mod-
ulated adenosine-mediated activation of CFTR channel activity
in cell-attached patches. We found that only inhibitors of PDE3
and PDE4 affected CFTR currents, with PDE4 inhibitors being
TABLE I
Summary of reverse transcription-PCR of PDE3 and PDE4
















FIG. 2. Selective PDE4 inhibitor al-
ters compartmentalized regulation
of CFTR. A, effect of PDE inhibitors on
regulation of CFTR-mediated Cl secre-
tion by ADO. RS25344 (0.3 M; ●), cilos-
tamide (1.0 M; Œ), or vehicle (H2O or
Me2SO; f) was added to the luminal bath.
Isc responses (Cl
 secretion) to increasing
concentrations of ADO were recorded and
plotted as a percentage of the maximum
forskolin-stimulated Isc. B, cAMP accu-
mulation stimulated by 10 M ADO in the
presence or absence of phosphodiesterase
inhibitors (1.0 M cilostamide or 0.3 M
RS25344) and the effect of 2 M forskolin.
The intracellular cAMP concentrations
are expressed in picomoles (n  3); error
bars indicate S.D. C, CFTR activity was
recorded in cell-attached patches of
Calu-3 cell apical membrane. Pipette volt-
age was clamped at 30 mV throughout.
CFTR channels open as upward deflec-
tions. Cultured epithelia were pretreated
with Me2SO/H2O (vehicle), 0.3 M
RS25344, or 1.0 M cilostamide (data not
shown). Activity was recorded for 240 s
(basal period). ADO (10 M) was intro-
duced into the luminal bath, and channel
activity was recorded for 300 s. Subse-
quently, forskolin (10 M) was added to
the luminal mixture to maximally stimu-
late CFTR. Inset shows a 10-s segment of
activity at higher resolution. D, summary
data from the experiments illustrated in
C. For each experimental condition, the
CFTR NPo (channel number  open prob-
ability) in the basal and ADO periods was
calculated and normalized to the value
observed during exposure to both ADO
and forskolin. Error bars, S.E. *, p 
0.001.
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the most efficacious (data not shown). On the basis of this
preliminary finding, we further characterized the expression of
these two groups of PDEs in the Calu-3 cell line, a model
system for exploring CFTR function in airway epithelia.
We monitored PDE enzyme activity in the presence of differ-
ent inhibitors, and we found that PDE3 and PDE4 families of
enzymes account for 	60% of the total activity (Fig. 1A). Be-
cause four distinct genes compose the PDE4 family, we further
analyzed the pattern of PDE4 expression in Calu-3 cells using
immunoprecipitation with isoform-specific antibodies. PDE4D
accounted for the majority (60%) of PDE4 activity in Calu-3
cells and, by inference, up to 	15% of total cAMP PDE activity
(Fig. 1B). These results are consistent with previous reports of
PDE expression in well-differentiated human bronchial epithe-
lium (WD-HBE) (20, 21) and with in situ hybridization studies
in mice (32). In a similar fashion, more than half of the total
PDE activity in WD-HBE was due to PDE4, and 	50% of PDE4
activity in these cells was immunoprecipitated with PDE4D-
selective antibodies.2
The presence of multiple PDE isoforms was confirmed by
reverse transcription-PCR analysis of PDE3 and PDE4 mRNA
expression in both Calu-3 cells and WD-HBE (Table I). Ampli-
cons corresponding to PDE3A, PDE3B, and the PDE4 families
were readily detected, consistent with our previous observa-
tions using PDE activity with the exception of PDE4C; how-
ever, this may reflect a transcription/translation disparity. Of
the nine known PDE4D gene-derived variants, transcripts cor-
responding to PDE4D3, PDE4D5, PDE4D7, and PDE4D9 were
amplified from Calu-3 cell mRNA. Western blot analysis of
immuno-enriched PDE4D from Calu-3 and WD-HBE cells in-
dicated that the most abundant gene products migrated on
SDS-PAGE as PDE4D5 and PDE4D7 (Fig. 1C). Western blots
using a PDE4D5-specific antiserum confirmed that this immu-
noreactivity is indeed due to PDE4D5 (data not shown).
We next tested whether inhibitors of PDE3 and PDE4 affect
CFTR Cl current in cultured Calu-3 monolayers after luminal
application of ADO. RS25344 (33), an inhibitor of PDE4
isozymes, modestly shifted the dose-response curve for ADO
stimulation of the CFTR to the left, whereas cilostamide, a
selective PDE3 inhibitor, had no effect (Fig. 2A). We next asked
whether PDE3 or PDE4 inhibitors affected total cellular cAMP
while simultaneously increasing CFTR responses to A2B stim-
ulation (Fig. 2B). In agreement with our previous observation
(2), luminal ADO alone did not increase total cAMP levels in
these cells. Interestingly, ADO in combination with PDE inhib-
itors also generated no detectable changes in total cAMP levels,
even when we used concentrations of ADO and PDE inhibitors
that maximally stimulated CFTR currents in patch clamp ex-
periments (described below). These data suggest that A2B re-
ceptors stimulate cAMP production in a local compartment
shared with AKAP-anchored PKA (4) and that the PKA in turn
phosphorylates and activates CFTR. To further characterize
the role of PDEs in local regulation of the CFTR, we next tested
the effect of PDE inhibitors on the ability of apical A2B recep-
tors to signal laterally to the CFTR contained within cell-
attached patches. In this paradigm, ADO added to the luminal
bath under control conditions did not effect the activation of the
CFTR within the patch (Fig. 2C), consistent with our previous
results (2). However, when Calu-3 cells were pretreated with
300 nM RS25344 (highly specific for PDE4 inhibition at this
concentration), ADO applied to the bath readily stimulated the
CFTR within the cell-attached patch. Indeed, when cultures
were pretreated with RS25344, ADO stimulated CFTR almost
as effectively as 10 M forskolin (Fig. 2C). In contrast to the
dramatic effect of RS25344, pretreatment with cilostamide, a
selective inhibitor of PDE3 isozymes, had no significant effect
on CFTR currents (Fig. 2D). Furthermore, similar results were
observed when comparing rolipram (PDE4 inhibitor) and mil-
rinone (PDE3 inhibitor; data not shown), suggesting that PDE4
2 A. P. Barnes, G. Livera, M. Conti, and S. L. Milgram, unpublished
observations.
FIG. 3. CFTR is regulated by apical
PDE4 activity. Apical patches were gen-
erated from Calu-3 cells in the outside-out
configuration. A, effect of rolipram on
CFTR in excised outside-out patches. The
horizontal dash at the left indicates chan-
nel closed. B, effect of rolipram on CFTR
in excised outside-out patches with 10 M
PKI in the pipette. C, effect of milrinone
on CFTR in excised outside-out patches.
D, summary data for A (n  11), B (n 
10), and C (n  7). *, p  0.02.
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isozymes are critically involved in modulating the spread of
cAMP signaling at the apical surface in Calu-3 cells. It is also
important to note that the effect of RS25344 on ADO stimula-
tion of CFTR in cell-attached patches appeared more dramatic
than the modest shift induced in the adenosine CFTR Isc dose-
response relation. The Calu-3 Isc is a composite of multiple
electrochemical driving forces and does not directly measure
apical conductance as described previously (34). Plausibly,
stimulation of apical anion conductance due to PDE inhibition
would not dominate Isc under these conditions.
Although these inhibitor studies strongly suggest that PDE4
isozymes limit the spread of subapical cAMP, we cannot rule
out the possibility that the cell-permeant inhibitors we used
acted indirectly through effectors located outside the subapical
domain of the cell. Therefore, we generated excised apical
membrane patches in the outside-out configuration from the
Calu-3 cells and exposed them to PDE3 and PDE4 inhibitors.
In this paradigm, traces indicate endogenous channel activity
because the patches were not stimulated with ADO. Channel
opening increased with increasing concentrations of the PDE4
inhibitor (Fig. 3A). To confirm that this observation results
from cAMP signaling through PKA and not through nonspecific
effects due to generation of the patch, we included PKI, a
PKA-specific inhibitor, in the pipette solution (Fig. 3B). To test
whether PDE3 isozymes were also associated with excised ap-
ical membrane patches, we added the PDE3 inhibitor milri-
none to the bath, but we saw no significant effect on channel
kinetics (Fig. 3, C and D). These data indicate that the mem-
brane and submembranous complexes associated with the
patch contain the components necessary for regulating CFTR
signaling and that this regulation involves factors sensitive to
inhibitors of PDE4. It is also important to note that in both
cell-attached and outside-out patches, both RS25344 and fors-
kolin are able to permeate the membrane, excluding the possi-
bility that the effects observed represent a physical barrier
created by the membrane geometry near the pipette tip.
The effect of PDE4 inhibitors on the CFTR in patches excised
from the apical membrane suggested that PDE4 is recovered in
the patch and, therefore, all the components controlling the open-
ing of the channel are in close proximity to each other. To further
assess this possibility, immunostaining was used to determine
the subcellular location of PDE4D in human airway epithelium.
The majority of PDE4D isoforms detected in human trachea,
particularly PDE4D5 (Fig. 4), are localized at or near the apical
membrane. This is consistent with the localization of other com-
ponents of the CFTR complex (35–37). Interactions with RACK-1
FIG. 4. Localization of PDE4D in airway epithelium. Ten-micrometer sections of human trachea were fixed in 4% formaldehyde, perme-
abilized, and incubated overnight with primary antibodies. A and B, immunohistochemical staining for PDE4D isoforms in human trachea using
monoclonal antisera. C and D, immunostaining of PDE4D5 isoform in human trachea using rabbit polyclonal sera. A and C, phase-contrast images
merged with the immunofluorescence signal detected with PDE4 antisera. Scale bars  10 M.
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(38), AKAP350 (12), and -arrestin (18) are known to direct the
subcellular localization of PDE4D5 in other tissues, however, it is
unclear whether these proteins play a role in directing the sub-
cellular distribution of PDE4D5 in airway epithelial cells. Any of
these targeting proteins would be consistent with existing data
concerning A2B receptor regulation (39), RACK1 localization in
Calu-3 cells (40), and localized PKA at the apical membrane (4).
This staining pattern supports and reinforces the conclusion that
an apically localized PDE4D pool contributes to the observed
biophysical properties seen in the excised patch experiments
described previously.
Close apposition of functionally relevant PDE isozymes with
the apical membrane supports the notion that cAMP signaling
downstream from apical A2B receptors in airways is finely
tuned. One factor that could contribute to this fine regulation is
the ability of PKA to increase the activity of long isoforms of
PDE4D including PDE4D5 (41, 42). To examine the possibility
that subapical cAMP levels may be regulated by a negative
feedback loop through PDE4, we measured the effect of A2B
stimulation on the activity of PDE4 in Calu-3 cells. Indeed,
luminal application of ADO or forskolin stimulated PDE4 ac-
tivity in cell lysates; this stimulation was mediated by PKA
because it was blocked by the PKA inhibitor Rp-cAMP (Fig.
5A). Thus, in addition to the already well-established roles of
PKA in transducing increases in cAMP, stimulation of PKA
activity in the apical membrane enhances the diffusional bar-
rier provided by localized PDE4. This observation supports the
presence of a mechanism that allows cells to co-regulate acti-
vation and deactivation of a signal transduction pathway using
a feedback loop.
Additional mechanisms reinforce the local regulation of
CFTR by cAMP and its metabolites. For example, CFTR cur-
rent is reduced by AMP-dependent protein kinase (AMPK), a
serine-threonine kinase activated by AMP and reported to di-
rectly bind the CFTR (43). Because of this direct interaction
and because 5-AMP is generated by the PDE-mediated metab-
olism of cAMP, we speculate that A2B receptor-driven stimu-
lation of subapical PDE4 could initiate negative feedback on
CFTR activity through AMPK. Preliminary data testing this
possibility indicate that pretreating Calu-3 cell monolayers
with the AMPK-activating compound 5-aminoimidazole-4-car-
boxamide riboside to fully activate AMPK reduces CFTR-me-
diated Cl secretion induced by luminal ADO (data not shown).
Furthermore, recent work from Randak and Welsh (44) indi-
cates that the CFTR harbors an intrinsic adenylate kinase
activity that may regulate channel gating by directly binding
AMP. Taken together, these findings support a complex and
interactive regulation of the CFTR through mechanisms that
both regulate and respond to local levels of cAMP and its
metabolites at the apical membrane.
Our data provide physical and functional evidence for a
major role of PDE4 as a diffusion barrier to cAMP signaling in
the apical membrane of airway epithelia. This spatial barrier of
PDEs is sensitive and proportional to the levels of local cAMP
(Fig. 5B). However, it should be noted that the effectiveness of
this barrier would also be dependent on the intensity and
duration of cellular stimulation because the excessive genera-
tion of cAMP in the microdomain may exceed the catalytic
capacity of the available PDEs. This model also includes a
potential downstream effector, AMPK. This kinase is known to
localize to the apical membrane (43), can down-regulate CFTR
currents in Calu-3 cells (45), and may be stimulated by the
locally increased 5-AMP generated by PDE activity near the
activated receptor/channel complex. Additional experiments
will be required to elucidate the exact relationship between the
5-AMP generated by PDE4 and AMPK activity in Calu-3 cells.
Our observations uncover a finely tuned orchestration of
signaling events at the apical membrane. Using cell-attached
FIG. 5. Protein kinase A activation
of PDE4 after ADO stimulation.
Calu-3 cells were incubated for 1 h in
serum-free Opti-MEM containing 300 M
AMPCP and then stimulated for 5 min
with 10 M ADO at 37 °C. A, increased
phosphodiesterase activity after apical
ADO or forskolin stimulation. This in-
crease is blocked by incubation with the
PKA inhibitor Rp-cAMP (RP) (1 mM). B,
cAMP metabolism at the apical mem-
brane can be self-regulating, and its by-
products also can regulate CFTR activity.
Activation of the adenosine A2B receptor
leads to stimulation of adenylyl cyclase by
Gs. The resulting increase in cAMP trig-
gers protein kinase A (R, regulatory; C,
catalytic) that is anchored near CFTR by
an protein kinase A-anchoring protein
(AKAP). CFTR open probability is in-
creased by PKA phosphorylation. PKA
also increases PDE4 activity that leads to
an attenuation of the cAMP signal. The
by-product of cAMP degradation can acti-
vate adenosine monophosphate-activated
kinase (AMPK), leading to CFTR down-
regulation.
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electrophysiology, we identified a mechanism by which cells
may limit cAMP effects to short distances from the apical
membrane. This observation represents an important insight
to the central issue of cell signaling fidelity and provides a
means by which a cell may spatially discriminate between
otherwise identical cAMP signals. With the inclusion of phos-
phodiesterases as the cellular component required for limited
ADO signaling, this work expands the earlier characterization
of the apical signaling complex that regulates CFTR currents
in the airway epithelium (2, 10). It also adds context to previous
observations about PDE activity in airway and the role of
cAMP and 5-AMP in apical signaling. These themes are im-
portant not only in understanding cellular physiology but also
in designing successful therapeutics for the treatment of
cystic fibrosis.
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